Request to Join
has invited you to join this group
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Piero Dalerba, M.D., Debashis Sahoo, Ph.D., Soonmyung Paik, M.D., Xiangqian Guo, Ph.D., Greg Yothers, Ph.D., Nan Song, Ph.D., Nate Wilcox-Fogel, M.S., Erna Forgó, M.D., Pradeep S. Rajendran, B.S., Stephen P. Miranda, B.A., Shigeo Hisamori, M.D., Ph.D., Jacqueline Hutchison, Tomer Kalisky, Ph.D., Dalong Qian, M.D., Norman Wolmark, M.D., George A. Fisher, M.D., Ph.D., Matt van de Rijn, M.D., Ph.D., and Michael F. Clarke, M.D.
N Engl J Med 2016; 374:211-222 | January 21, 2016 | DOI: 10.1056/NEJMoa1506597
The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice.
We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation across gene-expression arrays and then ranked candidate genes according to the availability of clinical-grade diagnostic assays. With the use of subgroup analysis involving independent and retrospective cohorts of patients with stage II or stage III colon cancer, the top candidate gene was tested for its association with disease-free survival and a benefit from adjuvant chemotherapy.
The transcription factor CDX2 ranked first in our screening test. A group of 87 of 2115 tumor samples (4.1%) lacked CDX2 expression. In the discovery data set, which included 466 patients, the rate of 5-year disease-free survival was lower among the 32 patients (6.9%) with CDX2-negative colon cancers than among the 434 (93.1%) with CDX2-positive colon cancers (hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002). In the validation data set, which included 314 patients, the rate of 5-year disease-free survival was lower among the 38 patients (12.1%) with CDX2 protein–negative colon cancers than among the 276 (87.9%) with CDX2 protein–positive colon cancers (hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003). In both these groups, these findings were independent of the patient’s age, sex, and tumor stage and grade. Among patients with stage II cancer, the difference in 5-year disease-free survival was significant both in the discovery data set (49% among 15 patients with CDX2-negative tumors vs. 87% among 191 patients with CDX2-positive tumors, P=0.003) and in the validation data set (51% among 15 patients with CDX2-negative tumors vs. 80% among 106 patients with CDX2-positive tumors, P=0.004). In a pooled database of all patient cohorts, the rate of 5-year disease-free survival was higher among 23 patients with stage II CDX2-negative tumors who were treated with adjuvant chemotherapy than among 25 who were not treated with adjuvant chemotherapy (91% vs. 56%, P=0.006).
Lack of CDX2 expression identified a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. (Funded by the National Comprehensive Cancer Network, the National Institutes of Health, and others).
Originally Appeared in The New England Journal of Medicine on January 21, 2016.